{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:08:18Z","timestamp":1782623298992,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019189","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The association between heart rate (HR) and clinical outcomes is well understood in patients with heart failure with reduced ejection fraction (HFrEF) but less clear in those with HFmrEF\/HFpEF, especially among individuals with atrial fibrillation (AF). In a prespecified analysis of the FINEARTS-HF trial, we examined the association between baseline HR and clinical outcomes by heart rhythm and evaluated finerenone\u2019s effect across the spectrum of HR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events. Heart rhythm (sinus rhythm or AF) was determined from the baseline ECG. Patients with pacemaker rhythm or missing HR\/rhythm data were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients with sinus rhythm (SR n = 3497; 62%), higher baseline HR was associated with a higher incidence rate for the primary outcome. In patients with AF (n = 2190; 38%), no association between HR and outcomes was observed. The effect of finerenone on the primary outcome was consistent across the HR spectrum, regardless of rhythm (P for interaction = 0.96 in SR; 0.49 in AF). In patients with SR, there was no significant HR change with finerenone versus placebo. In AF patients, finerenone led to a small but statistically significant HR reduction: a placebo-corrected decrease of 1.35\u2005bpm (95% CI: 0.41\u20132.29) from baseline to 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with HFpEF\/HFmrEF in FINEARTS-HF, higher baseline HR was associated with a higher risk of the primary outcome in patients with SR but not in those with AF. Finerenone's effect on the primary outcome was consistent across the HR spectrum, irrespective of rhythm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT04435626<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag008","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:54:44Z","timestamp":1767963284000},"page":"26-38","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial"],"prefix":"10.1093","volume":"28","author":[{"given":"Misato","family":"Chimura","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-4906","authenticated-orcid":false,"given":"Alasdair D","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-5773","authenticated-orcid":false,"given":"Andrea","family":"Scalise","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Heart Centre Singapore and Duke\u2013National University of Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Milano-Bicocca and Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm Clinical Investigation Centre, CHU, Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026050209113588900_xuag008-B1","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/eurheartj\/ehaf291","article-title":"Heart rate-lowering drugs and outcomes in hypertension and\/or cardiovascular disease: a meta-analysis","volume":"46","author":"Sanidas","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209113588900_xuag008-B2","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/s0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2026050209113588900_xuag008-B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026050209113588900_xuag008-B4","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/s0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"2026050209113588900_xuag008-B5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.1682","article-title":"Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/ejhf.346","article-title":"Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis","volume":"17","author":"Simpson","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B8","doi-asserted-by":"publisher","first-page":"e010898","DOI":"10.1161\/circheartfailure.123.010898","article-title":"Efficacy of dapagliflozin according to heart rate: a patient-level pooled analysis of DAPA-HF and DELIVER","volume":"16","author":"Kondo","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026050209113588900_xuag008-B9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of if-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial","volume":"62","author":"Kosmala","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026050209113588900_xuag008-B10","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/circulationaha.115.017119","article-title":"Effect of selective heart rate slowing in heart failure with preserved ejection fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"2026050209113588900_xuag008-B11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","article-title":"\u03b2-blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction","volume":"9","author":"Palau","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026050209113588900_xuag008-B13","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026050209113588900_xuag008-B14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0031-6997(25)06926-1","article-title":"Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla","volume":"24","author":"Wurtman","year":"1972","journal-title":"Pharmacol Rev"},{"key":"2026050209113588900_xuag008-B15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050209113588900_xuag008-B16","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"2026050209113588900_xuag008-B19","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","article-title":"A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"2026050209113588900_xuag008-B20","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ejhf.2677","article-title":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-preserved trial","volume":"24","author":"B\u00f6hm","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B21","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/eurjhf\/hft093","article-title":"Lenient vs. Strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study","volume":"15","author":"Mulder","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026050209113588900_xuag008-B22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus strict rate control in patients with atrial fibrillation","volume":"362","author":"Van Gelder","year":"2010","journal-title":"N Engl J Med"},{"key":"2026050209113588900_xuag008-B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jchf.2012.09.002","article-title":"Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis","volume":"1","author":"Rienstra","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026050209113588900_xuag008-B24","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.clinthera.2015.08.017","article-title":"Should \u03b2-blockers be used in patients with heart failure and atrial fibrillation?","volume":"37","author":"Mareev","year":"2015","journal-title":"Clin Ther"},{"key":"2026050209113588900_xuag008-B25","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/s0140-6736(14)62340-0","article-title":"\u03b2 blockers, atrial fibrillation, and heart failure","volume":"384","author":"McMurray","year":"2014","journal-title":"Lancet"},{"key":"2026050209113588900_xuag008-B26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamacardio.2025.0848","article-title":"Finerenone and atrial fibrillation in heart failure: a secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Matsumoto","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026050209113588900_xuag008-B27","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis","volume":"85","author":"Pabon","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag008\/66420924\/xuag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/26\/66420924\/xuag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/26\/66420924\/xuag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:11:45Z","timestamp":1777727505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/1\/26\/8426313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag008","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}